Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

Click for more information

0.00%

8.0¢ kazia therapeutics limited

and I guess the other concern is that the trial status is still...

First 1329 Last

Share
Profile

Follow
spyglass

1,345 Posts.

141

12/03/21

09:31

Post #: 51710302
Share

Originally posted by spyglass: ↑

BCBM results are concerning me as there doesn't appear to be anything at AACR.

I'm no expert on things medical, so I can see 2 options:

1) results are not worth publishing. James has mentioned that they did not expect all trials to be successful. I would have thought though that if this was the case then the researchers would put something out, or if they didn't want to publish (do they have to?) then they'd advise the company who would then release information to the market. As that has not (yet) happened, I'm hopeful that point 2 is what is happening

2) the results are really good and the criteria for interim reporting has not been met. However the trial information says a secondary outcome was clinical benefit at 18 and 24 weeks so I would have though that would be reported by now.

So I'd welcome anyone with any sort of knowledge on the reporting of clinical trials to put their thoughts out there.

Expand

and I guess the other concern is that the trial status is still showing as recruiting, so maybe they haven't got enough data yet?
https://www.clinicaltrials.gov/ct2/show/record/NCT03765983

KZA Price at posting: $1.34 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

HLX

Helix investor makes partial takeover bid, proposing board changes

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

There are more pages in this discussion • 738 more messages in this thread...

First 1329 Last

Add KZA (ASX) to my watchlist

SPONSORED BY